The intersection of eating disorders and diabetes mellitus represents one of the most challenging clinical scenarios in modern medicine. When these conditions co-occur, patients face a bidirectional relationship where disordered eating behaviors disrupt glycemic control, and the demands of diabetes management can exacerbate or trigger eating disorder pathology. Pharmacotherapy, when carefully selected and monitored, can serve as a critical component of a comprehensive treatment plan. This article provides an in-depth examination of how medications can be used safely and effectively in patients with comorbid eating disorders and diabetes, covering specific drug classes, mechanisms of action, clinical considerations, and strategies for optimizing outcomes while minimizing risks.

Understanding the Scope and Complexity of Comorbid Eating Disorders and Diabetes

Eating disorders, including anorexia nervosa, bulimia nervosa, binge-eating disorder, and other specified feeding or eating disorders, occur at disproportionally higher rates in individuals with diabetes compared to the general population. In type 1 diabetes, prevalence estimates for comorbid eating disorders range from 10% to 40%, with the distinct syndrome of diabulimia—the intentional restriction or omission of insulin to control weight—representing a particularly dangerous manifestation. Among those with type 2 diabetes, binge-eating disorder is the most common comorbid eating disorder, affecting up to 8–15% of patients, and is strongly associated with obesity, poor glycemic control, and increased cardiovascular risk.

The relationship is complex. Eating disorder behaviors—such as severe caloric restriction, purging via vomiting or laxative abuse, and binge eating followed by compensatory insulin restriction—directly impair blood glucose management. Conversely, the chronic stress of diabetes self-care, weight gain associated with insulin therapy, and the relentless focus on food and numbers can precipitate or worsen eating disorder symptoms. This bidirectional interplay demands a treatment approach that addresses both conditions simultaneously rather than sequentially.

Core Principles of Pharmacotherapy in This Dual Population

Pharmacotherapy for comorbid eating disorders and diabetes must be guided by several foundational principles. First, medication selection must account for the metabolic and psychiatric effects of each drug, avoiding agents that exacerbate eating disorder symptoms or cause dangerous glycemic fluctuations. Second, dosing and monitoring require heightened vigilance due to altered pharmacokinetics from malnutrition, purging behaviors, or diabetic complications. Third, no single medication can replace structured psychotherapy and medical nutrition therapy; pharmacotherapy is an adjunctive tool, not a standalone solution.

A multidisciplinary team—including an endocrinologist, psychiatrist or eating disorder specialist, registered dietitian, and psychologist—should collaboratively design and oversee the pharmacologic plan. Baseline assessments of glycemic control (HbA1c, continuous glucose monitoring data), weight stability or trajectory, electrolyte levels, and psychiatric status are essential before starting or adjusting medications.

Pharmacotherapy for Eating Disorders in the Context of Diabetes

Medications approved or commonly used for eating disorders must be evaluated carefully in patients with diabetes due to potential interactions with glucose metabolism, appetite, and weight.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs such as fluoxetine and sertraline are first-line pharmacotherapy for bulimia nervosa and binge-eating disorder, with fluoxetine specifically approved by the FDA for bulimia. These agents reduce the frequency of binge eating and purging episodes and improve comorbid depression and anxiety. In patients with diabetes, SSRIs are generally well-tolerated, but clinicians must monitor for potential weight changes—some patients may experience modest weight loss initially, while long-term use can lead to weight gain. Fluoxetine, in particular, tends to be weight-neutral for many. Additionally, SSRIs can slightly increase insulin sensitivity, which may require downward adjustment of insulin doses. Starting at low doses and titrating gradually is prudent to minimize side effects such as gastrointestinal distress, which could disrupt eating patterns.

Antipsychotics

Second-generation antipsychotics, most notably olanzapine, are sometimes used off-label for anorexia nervosa, particularly for patients with severe weight loss and refractory obsessive thoughts about eating and body image. Olanzapine can promote weight gain and reduce anxiety, but it carries significant metabolic risks—hyperglycemia, dyslipidemia, and weight gain—that are especially concerning in patients with diabetes. If an antipsychotic is deemed necessary, aripiprazole or ziprasidone may be preferred due to more favorable metabolic profiles, though evidence in anorexia nervosa is limited. In all cases, baseline and periodic monitoring of fasting glucose, lipids, and weight is mandatory. Diabetes medications may need adjustment if antipsychotic therapy is initiated.

Anticonvulsants

Topiramate, an anticonvulsant, has shown efficacy in reducing binge eating episodes and promoting weight loss in binge-eating disorder. It may also have some benefit in bulimia nervosa. For patients with type 2 diabetes who are overweight or obese, topiramate's weight-reducing effects can be advantageous. However, it can cause cognitive side effects (e.g., word-finding difficulties, drowsiness) that may impair diabetes self-care, and it requires renal function monitoring. Topiramate is not typically used in anorexia nervosa due to its appetite-suppressing effects.

Lisdexamfetamine

Lisdexamfetamine is the only FDA-approved medication for moderate-to-severe binge-eating disorder. It reduces binge eating frequency effectively, but it is a central nervous system stimulant and can suppress appetite, leading to further weight loss—a risk in patients with underlying restrictive eating patterns. Additionally, stimulants can cause tachycardia and elevated blood pressure, which must be monitored. Its use in diabetes requires cautious selection; it may be appropriate for patients with binge-eating disorder and type 2 diabetes who need appetite control and weight reduction, but it is contraindicated in those with anorexia or significant restriction. Patients must be educated about the risk of misuse and dependence.

Pharmacotherapy for Diabetes in Patients with Eating Disorders

Managing glucose-lowering medications in the presence of an eating disorder demands flexibility, safety, and a deep understanding of the patient's behavioral patterns.

Insulin

Insulin is essential for type 1 diabetes and often necessary for type 2 diabetes. In patients with eating disorders, particularly those with restriction or purging behaviors, insulin dosing becomes a critical intervention point. The risk of diabulimia—intentional insulin omission—must be assessed and addressed. Collaboration between the patient, endocrinologist, and mental health provider is vital to rebuild trust and develop safe insulin regimens. The use of continuous glucose monitoring (CGM) and insulin pumps can provide additional safety by alerting patients and providers to rapid fluctuations in glucose, and by reducing the need for frequent manual injections, which can be a trigger for restriction. Clinicians should avoid rigid glycemic targets that could reinforce perfectionism or fear of food, and instead aim for realistic, forgiving goals such as time-in-range (70–180 mg/dL) with low hypoglycemia risk.

Metformin

Metformin remains first-line therapy for type 2 diabetes due to its efficacy, safety, and weight-neutral profile. It does not cause hypoglycemia and can modestly improve insulin sensitivity. In patients with binge-eating disorder and type 2 diabetes, metformin may help mitigate weight gain and improve metabolic parameters without the hunger-amplifying effect of sulfonylureas. However, gastrointestinal side effects (nausea, diarrhea) can exacerbate food aversions in patients with restrictive behaviors; these issues often resolve with slow titration or extended-release formulations. Metformin should be discontinued if weight loss is severe or if the patient is at risk for lactic acidosis (rare, but possible with dehydration from purging).

GLP-1 Receptor Agonists

GLP-1 receptor agonists (e.g., semaglutide, liraglutide, exenatide) are increasingly popular for type 2 diabetes because of their potent glucose-lowering effects and significant weight loss benefits. However, these medications must be used with extreme caution in patients with comorbid eating disorders. They delay gastric emptying and suppress appetite, which can be dangerous for patients with anorexia nervosa or any history of severe restriction, as they can precipitate further weight loss and malnutrition. For patients with binge-eating disorder and type 2 diabetes, GLP-1 agonists may be beneficial by reducing hyperphagia and improving satiety. Observational data suggest they may also reduce binge eating frequency, though formal FDA approval for this indication is lacking. Careful monitoring of weight, nutritional intake, and electrolyte status is mandatory, and the medication should be discontinued if significant weight loss occurs.

SGLT2 Inhibitors

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) offer renal and cardiovascular benefits in addition to glycemic control and weight loss. Their mechanism of action is independent of food intake, which makes them less likely to be influenced by eating disorder behaviors. However, they carry risks of dehydration, hypotension, and euglycemic diabetic ketoacidosis (DKA)—especially if the patient restricts insulin, purges, or fasts. These risks are magnified in eating disorder populations. SGLT2 inhibitors should be used only in stable patients without a history of severe restriction or purging, and with clear instructions to hold the medication if vomiting, diarrhea, or reduced oral intake occurs. Patient education about the symptoms of DKA is essential.

Special Considerations for Type 1 Diabetes and Diabulimia

Diabulimia is a life-threatening behavior pattern where individuals with type 1 diabetes intentionally restrict or omit insulin doses to cause rapid weight loss via glucosuria and catabolism. It is not a formal DSM-5 diagnosis but is recognized as a subtype of eating disorder in type 1 diabetes. Pharmacotherapy for the eating disorder component is challenging because SSRIs or other psychiatric medications alone are insufficient; the primary intervention requires intensive psychotherapy (e.g., cognitive behavioral therapy, dialectical behavior therapy) and a collaborative medical-psychiatric care team. Insulin must be reintroduced or optimized gradually—often starting with long-acting basal insulin and rapid-acting analogs for meals—while the patient learns to separate insulin use from weight control. Adjunctive medications such as low-dose olanzapine or topiramate have been tried, but evidence is weak. Inpatient medical stabilization may be needed if DKA, severe hypoglycemia, or electrolyte disturbances are present.

Challenges and Risks of Pharmacotherapy

Several challenges complicate pharmacotherapy in this population. Drug-drug interactions between psychiatric medications and diabetes agents can alter glucose metabolism. For example, SSRIs may enhance insulin sensitivity and cause hypoglycemia if insulin doses are not adjusted. Antipsychotics can cause hyperglycemia and require metformin or other agents for mitigation. Medication non-adherence is common, driven by both eating disorder cognitions and the burden of polypharmacy. Purging behaviors (vomiting, laxative abuse) can alter drug absorption, reduce medication efficacy, and increase the risk of electrolyte disturbances (hypokalemia, hypomagnesemia), which can be exacerbated by diuretics or SGLT2 inhibitors. Routine monitoring of electrolytes, renal function, blood counts, and glucose logs is non-negotiable.

Another critical issue is medication misuse. Patients with eating disorders may abuse certain drugs for weight control, such as stimulants, thyroid hormone, or insulin omission. Providers should screen for medication misuse at each visit and maintain a low threshold for involving a psychiatrist or addiction specialist. Prescribing controlled substances like lisdexamfetamine requires risk-benefit assessment and strict monitoring.

The Role of a Multidisciplinary Team

Optimal pharmacotherapy cannot occur in isolation. The treatment team must include professionals who understand both metabolic and psychiatric complexities. Endocrinologists or primary care providers with diabetes expertise can prescribe and monitor diabetes medications, adjusting doses based on CGM data and behavioral patterns. Psychiatrists can manage eating disorder medications, monitor for psychiatric side effects, and coordinate with therapists. Registered dietitians provide medical nutrition therapy that respects the patient's relationship with food while meeting nutritional needs. Psychotherapists address the underlying cognitive distortions, body image concerns, and coping deficits. Regular case conferences or shared note access ensure continuity and prevent conflicting recommendations.

Behavioral health integration is especially important when considering medications that affect appetite or weight. For example, a patient with anorexia nervosa should not be prescribed a GLP-1 agonist without careful assessment of motivation and capacity for weight restoration. The team should agree on weight and nutritional goals before initiating any medication that could impact food intake.

Monitoring and Safety Protocols

Once pharmacotherapy is initiated, a structured monitoring plan is essential. This should include: weekly or biweekly weight checks (with the patient blinded to the number if weight gain triggers distress), daily CGM review (if available) for hypoglycemia and hyperglycemia patterns, periodic HbA1c (every 3 months), comprehensive metabolic panel and electrolyte panel (every 1–3 months, or more frequently if purging), and psychiatric assessments for mood changes, suicidality, or worsening eating disorder symptoms. Patient-reported outcomes such as the Eating Disorder Examination Questionnaire (EDE-Q) or the SCOFF questionnaire can be used to track behavioral changes.

The emergence of severe hypoglycemia in a patient on insulin or sulfonylurea requires immediate evaluation for insulin omission or excessive exercise as part of an eating disorder. Conversely, persistent hyperglycemia despite apparent medication adherence may indicate purging behaviors, insulin restriction, or unrecognized hyperphagia. Open, nonjudgmental communication is crucial to uncovering the root cause.

Future Directions in Pharmacotherapy

Research into targeted pharmacotherapy for comorbid eating disorders and diabetes remains nascent. Promising avenues include the development of medications that simultaneously address glycemic control and eating disorder pathology. For instance, dual agonists of GLP-1 and GIP (such as tirzepatide) are being studied for weight management and binge eating, and early results are encouraging. However, their safety in restrictive eating disorders is unknown. Additionally, the role of intranasal insulin in modulating food reward and cognitive flexibility is being explored, but clinical data are limited.

Finally, large-scale pragmatic trials comparing comprehensive integrated care models (with pharmacotherapy as one component) versus usual care are needed to establish evidence-based protocols. The importance of patient-centered outcomes—including quality of life, treatment satisfaction, and functional recovery—must be emphasized alongside metabolic endpoints.

Conclusion

Pharmacotherapy is an indispensable, yet high-risk, component of treatment for patients with comorbid eating disorders and diabetes. Successful pharmacologic management requires careful consideration of each drug's mechanism, metabolic effects, and potential for misuse, combined with robust monitoring and a collaborative team approach. No medication can substitute for the psychological and behavioral work of recovery, but when used judiciously, pharmacotherapy can stabilize mood, reduce disordered eating behaviors, improve glycemic control, and ultimately enhance the quality of life for these complex patients. Continued research and clinical innovation are needed to expand the armamentarium and refine treatment paradigms for this vulnerable population.